Mar 13, 2021 / 12:00PM GMT
Samantha Budd Haeberlein - Biogen Inc. - VP of Clinical Development
Hello. My name is Samantha Budd Haeberlein. I'm from Biogen. And in this presentation, I will present the evaluation of aducanumab efficacy in early Alzheimer's disease. This will be followed by a presentation by my colleague, Dr. Spyros Chalkias, on the safety in -- of aducanumab in early Alzheimer's disease.
Here are the author disclosures. And just to remind that I may be making forward-looking statements during this presentation.
Aducanumab is an investigational drug whose efficacy and safety have not yet been established, and it is not approved for use in any country. The aducanumab Phase III trials that are called EMERGE and ENGAGE were 2 identically designed, 18-month in duration clinical trials that enrolled 3,285 patients at 348 sites in 20 countries. The patient population were those with early Alzheimer's disease with the diagnosis of either MCI due to Alzheimer's disease or mild Alzheimer's disease at entry to the study. All patients were confirmed for the presence of amyloid pathology. 2 dosing regimens were
Biogen Inc Evaluation of aducanumab safety in early Alzheimer's disease at AD/PD Transcript
Mar 13, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers